Nurix Therapeutics, Inc. Website

Nurix Therapeutics, Inc.

NasdaqGM-NRIX

Company Overview

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

  • Name

    Nurix Therapeutics, Inc.

  • CEO

    Arthur T. Sands

  • Website

    www.nurixtx.com

  • Sector

    Biotechnology

  • Year Founded

    2009

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Nurix Therapeutics Inc: Surge in Stock Price Driven by Positive Trial Results and Analyst Optimism

  • Nurix Therapeutics reported impressive Phase 1 trial results for bexobrutideg, boosting investor confidence.
  • Analysts have shown strong support for NRIX, raising price targets amid positive feedback on recent developments.
  • The company's strategic focus on oncology and immunology positions it favorably within the biotech sector.

Over the past month, Nurix Therapeutics Inc (NRIX) experienced a remarkable increase of 52.5%, significantly outperforming the S&P 500's modest return of 0.7%. This surge can be attributed to key developments and positive market sentiment surrounding its innovative therapies. Notably, on December 8, the company announced impressive Phase 1 trial results for its investigational drug bexobrutideg, which demonstrated a substantial objective response rate in patients with relapsed or refractory Waldenström macroglobulinemia. The favorable data presented at the American Society of Hematology Annual Meeting solidified investor confidence and contributed to a notable rise in share value.

Throughout this period, analysts maintained bullish sentiments towards NRIX. Mizuho upheld an Outperform rating while increasing its price target to $30 due to encouraging feedback from key opinion leaders regarding chronic lymphocytic leukemia (CLL). Similarly, HC Wainwright & Co.'s decision to raise their price target further underscored optimism about Nurix’s prospects within the biotech sector.

Despite some bearish fluctuations during this timeframe—such as insider trading activity that raised concerns among investors—the overall narrative remained largely positive. Social media discussions highlighted strong investor interest around upcoming presentations at major conferences like ASH 2025. These conversations emphasized both short-term catalysts and long-term investment perspectives centered on protein degrader technologies.

Nurix's strategic positioning within oncology and immunology has played a crucial role in shaping market perceptions positively. As NRIX continues enrolling patients for pivotal studies like Daybreak while showcasing promising data from ongoing trials, it remains well-positioned for sustained growth moving forward.

Overall, Nurix Therapeutics Inc outperformed not only the S&P but also exceeded expectations relative to broader health care sector performance by an impressive margin of 50.6%.

NasdaqGM:NRIX